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The advent of next-generation sequencing (NGS) has led to the way to the identification of a 
plethora of additional mutations in acute myeloid leukaemia (AML).    These mutations, genetic and 
epigenetic alterations, have all been reported to positively or negatively associate with AML 
outcome.     Some of the mutations identified prior to NGS have been extensively studied, such the 
internal tandem duplication (ITD) of the FLT3 gene, mutations of the NPM1 or CEPBA genes and 
have been included in the WHO classification of AML as defining specific sub-categories of patients 
with normal karyotypes.      
The DNA (cytosine-5)-methyltransferase 3 alpha (DNMT3A) gene was identified by NGS and was 
shown to be mutated in approximately 20-35% of patients(Ley et al, 2010); this places it as one of 
the most frequently mutated genes in AML (Thol et al, 2011).    The majority of mutations occur in 
the methyltransferase domain and involves the R882 codon  
The value of determining minimal residual disease (MRD) levels has been clearly demonstrated in 
blood cancers notably with the regular monitoring of the BCR-ABL levels in chronic myeloid 
leukaemia (CML) (Hanfstein et al, 2012) and PML-RARa in acute promyelocytic leukaemia 
(APL)(Grimwade et al, 2015).   In each of these diseases, the failure to reduce the leukaemic clone 
burden below the level of conventional PCR detection or an increasing level of the fusion genes has 
been shown to be associated with the impending onset of disease resistance or clonal evolution.  
These signs could be used to alter therapeutic options to improve the patient’s outcome trajectory.   
The relevance of the prognostic significance of persistent DNMT3A mutations has been examined in 
four studies prior to the one reported in this issue.   Two have reported that the presence of 
DNMT3A mutations is associated with a poor clinical outcome (Hou et al, 2012;Klco et al, 2015); 
whilst the other two reported no difference in outcome (Debarri et al, 2015;Ploen et al, 2014). There 
are also differences in the size of the sample population, detection methodologies and the type of 
mutations analyzed 
To clarify this situation, Bhatnagar and colleagues have reported in this issue (REF) a study on a larer 
cohort of AML patients who had a dominant clone with DNMT3A R882 mutation at diagnosis.  All the 
patients received intensive induction treatment within Cancer and Leukemia Group B (CALGB) trial 
protocols.   Additional samples were then obtained when the patients had achieved a complete 
remission (CR) and both the diagnostic and CR samples were analyzed using a targeted NGS 
approach covering 35 genes.  For the determination of positivity of DNMT3A mutations, a detection 
level cut-off of >3% was used.   It should be noted that this study only included patients with a R882 
mutation in DNMT3A and the influence of other mutations were not assessed.   
At diagnosis, all the patients had at least one mutation in addition to the DNMT3A; with the level of 
DNMT3A mutation between 40-53%.   However, the interesting aspect was observed after patients 
had obtained CR where two cohorts were identified:  in approximately 24% of patients (cohort 1) no 
mutations were; whilst in cohort 2 (76%) a DNMT3A mutation persisted beyond CR with levels 
ranging from 3% to 45%    Surprisingly, there was no significant difference between overall survival 
(OS) or disease-free survival (DFS) between cohort 1 and 2; irrespective of the time that the CR was 
taken post morphological confirmation of CR or if the sample was within 30 day of CR being 
confirmed.  This is contrast to expectation from studies on CML and APL where the clearance or non-
detection of a mutation, albeit a fusion gene rather than a point mutation, is highly significant in 
terms of predicting outcome.    However, the persistence of DNMT3A R882 mutation post-CR 
appears not to have any impact on outcome.   
Within cohort 2, DNMT3a mutations alone were detected in around 3/4 (~73%) of the patients in the 
second cohort (cohort 2a); with the remaining 12 patients (~27%) having a DNMT3A mutation and 
one additional mutation (cohort 2b) mainly TET2, p53 or ASXL1.   Although no significant difference 
was seen for OS between cohorts 2a and 2b, the author report a “trend” (p=0.06) for patients with 
additional mutations post-CR to have poorer DFS.   
To complicate the situation further, the second mutation detected in patients in cohort 2b was 
different from any mutation identified, in that patient, at diagnosis in 50% of these cases; indicative 
of clonal evolution and expansion although the whether these additional mutations contributed to 
relapse was not investigated.      
Whilst this study has shown that persistence of mutations, at least for DNMT3A R882, has no or little 
impact on patient outcome it also raises questions around MRD monitoring.   For example, it has 
demonstrated that the use of NGS at <3% detection level is not viable for MRD so perhaps less (or 
even more) sensitive methods, including conventional PCR, would enable discrimination between 
clearance and persistence in terms of outcome.  Furthermore, the presence of DNMT3A mutations 
have been detected in healthy individuals with clonal haematopoiesis, increasing with age; so it is 
possible that their persistence demonstrated here is a reflection of “normal” haematopoiesis.  
However, the fact that the percent of patient’s disease free or alive at 3 or 5 years was similar 
irrespective of DNMT3A R882 clearance or persistence highlights that AML is not only clinically and 
biologically heterogeneous at diagnosis but this complexity is maintained throughout disease 
progression.   
References 
 
Debarri,H., Lebon,D., Roumier,C., Cheok,M., Marceau-Renaut,A., Nibourel,O., Geffroy,S., 
Helevaut,N., Rousselot,P., Gruson,B., Gardin,C., Chretien,M.L., Sebda,S., Figeac,M., 
Berthon,C., Quesnel,B., Boissel,N., Castaigne,S., Dombret,H., Renneville,A., & 
Preudhomme,C. (2015) IDH1/2 but not DNMT3A mutations are suitable targets for minimal 
residual disease monitoring in acute myeloid leukemia patients: a study by the Acute 
Leukemia French Association. Oncotarget, 6, 42345-42353. 
Grimwade,D., Ivey,A., & Huntly,B.J.P. (2015) Molecular landscape of acute myeloid leukemia in 
younger adults and its clinical relevance. Blood, 127, 29-41. 
Hanfstein,B., Muller,M.C., Hehlmann,R., Erben,P., Lauseker,M., Fabarius,A., Schnittger,S., 
Haferlach,C., Gohring,G., Proetel,U., Kolb,H.J., Krause,S.W., Hofmann,W.K., Schubert,J., 
Einsele,H., Dengler,J., Hanel,M., Falge,C., Kanz,L., Neubauer,A., Kneba,M., Stegelmann,F., 
Pfreundschuh,M., Waller,C.F., Branford,S., Hughes,T.P., Spiekermann,K., Baerlocher,G.M., 
Pfirrmann,M., Hasford,J., Saussele,S., & Hochhaus,A. (2012) Early molecular and cytogenetic 
response is predictive for long-term progression-free and overall survival in chronic myeloid 
leukemia (CML). Leukemia, 26, 2096-2102. 
Hou,H.A., Kuo,Y.Y., Liu,C.Y., Chou,W.C., Lee,M.C., Chen,C.Y., Lin,L.I., Tseng,M.H., Huang,C.F., 
Chiang,Y.C., Lee,F.Y., Liu,M.C., Liu,C.W., Tang,J.L., Yao,M., Huang,S.Y., Ko,B.S., Hsu,S.C., 
Wu,S.J., Tsay,W., Chen,Y.C., & Tien,H.F. (2012) DNMT3A mutations in acute myeloid 
leukemia: stability during disease evolution and clinical implications. Blood, 119, 559-568. 
Klco,J.M., Miller,C.A., Griffith,M., Petti,A., Spencer,D.H., Ketkar-Kulkami,S., Wartman,L.D., 
Christopher,M., Lamprecht,T.L., Helton,N.M., Duncavage,E.J., Payton,J.E., Baty,J., Heath,S.E., 
Griffiths,E.A., Shen,D., Hundal,J., Chang,G.S., Fulton,R., O'Laughlin,M., Fronick,C., Magrini,V., 
Demeter,R.T., Larson,D.E., Kulkarni,S., Ozenberger,B.A., Welch,J.S., Walter,M.J., 
Graubert,T.A., Westervelt,P., Radich,J.P., Link,D.C., Mardis,E.R., DiPersio,J.F., Wilson,R.K., & 
Ley,T.J. (2015) Association between mutation clearance after induction therapy and 
outcomes in acute myeloid leukemia. JAMA, 314, 811-822. 
Ley,T.J., Ding,L., Walter,M.J., McLellan,M.D., Lamprecht,T., Larson,D.E., Kandoth,C., Payton,J.E., 
Baty,J., Welch,J., Harris,C.C., Lichti,C.F., Townsend,R.R., Fulton,R.S., Dooling,D.J., 
Koboldt,D.C., Schmidt,H., Zhang,Q., Osborne,J.R., Lin,L., O'Laughlin,M., McMichael,J.F., 
Delehaunty,K.D., McGrath,S.D., Fulton,L.A., Magrini,V.J., Vickery,T.L., Hundal,J., Cook,L.L., 
Conyers,J.J., Swift,G.W., Reed,J.P., Alldredge,P.A., Wylie,T., Walker,J., Kalicki,J., Watson,M.A., 
Heath,S., Shannon,W.D., Varghese,N., Nagarajan,R., Westervelt,P., Tomasson,M.H., 
Link,D.C., Graubert,T.A., DiPersio,J.F., Mardis,E.R., & Wilson,R.K. (2010) DNMT3A Mutations 
in Acute Myeloid Leukemia. The New England Journal of Medicine, 363, 2424-2433. 
Ploen,G.G., Nederby,L., Guldberg,P., Hansen,M., Ebbesen,L.H., Jensen,U.B., Hokland,P., & 
Aggerholm,A. (2014) Persistence of DNMT3A mutations at long-term remission in adult 
patients with AML. Br.J Haematol, 167, 478-486. 
Thol,F., Damm,F., Ludeking,A., Winschel,C., Wagner,K., Morgan,M., Yun,H., Gohring,G., 
Schlegelberger,B., Hoelzer,D., Lubbert,M., Kanz,L., Fiedler,W., Kirchner,H., Heil,G., Krauter,J., 
Ganser,A., & Heuser,M. (2011) Incidence and Prognostic Influence of DNMT3A Mutations in 
Acute Myeloid Leukemia. Journal of Clinical Oncology. 
 
 
 
